Cell division cycle 37 change after bortezomib-based induction therapy helps to predict clinical response and prognosis in multiple myeloma patients

Cell division cycle 37 change after bortezomib-based induction therapy helps to predict clinical response and prognosis in multiple myeloma patients

ABSTRACTObjective Cell division cycle 37 (CDC37) modulates disease progression and bortezomib resistance in multiple myeloma by regulating X-box binding protein 1, nuclear factor-kappa-B, etc. This study aimed to explore the prognostic implication of CDC37 before and after bortezomib-based induction...

Full description

Bibliographic Details
Main Authors: Wuqiang Lin, Xiuli Chen, Heyong Zheng, Zhenjie Cai
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Hematology
Subjects:
Multiple myeloma
bortezomib-based induction treatment
cell division cycle 37
longitudinal change
response and survival
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2023.2231741

Internet

https://www.tandfonline.com/doi/10.1080/16078454.2023.2231741

Similar Items